The therapeutic antitumor effects generated by AnxA5-E7 vaccination following cisplatin treatment is CD8+ T cell dependent, as the administration of anti-CD8 neutralizing antibody abolished the ability of cisplatin and AnxA5-E7 treatment mice to control TC-1 tumor growth (Supplementary Fig. 11). Here, ANXA5 is linked to neoplasm.